Oppenheimer & Co. Inc. Purchases Shares of 17,885 Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Oppenheimer & Co. Inc. purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 17,885 shares of the company’s stock, valued at approximately $209,000.

Several other institutional investors have also added to or reduced their stakes in NTLA. Whipplewood Advisors LLC bought a new stake in shares of Intellia Therapeutics in the 4th quarter valued at approximately $40,000. KBC Group NV lifted its stake in shares of Intellia Therapeutics by 62.4% in the 4th quarter. KBC Group NV now owns 6,093 shares of the company’s stock valued at $71,000 after purchasing an additional 2,340 shares during the last quarter. AdvisorNet Financial Inc lifted its stake in shares of Intellia Therapeutics by 96.4% in the 4th quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock valued at $118,000 after purchasing an additional 4,950 shares during the last quarter. LMG Wealth Partners LLC bought a new stake in shares of Intellia Therapeutics in the 4th quarter valued at approximately $130,000. Finally, Green Alpha Advisors LLC bought a new stake in shares of Intellia Therapeutics in the 4th quarter valued at approximately $138,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Insider Buying and Selling at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 29,000 shares of company stock valued at $352,551 in the last ninety days. Corporate insiders own 3.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $9.00 price objective on shares of Intellia Therapeutics in a research note on Friday, February 28th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. Truist Financial lowered their price objective on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. William Blair reissued a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a research note on Monday, November 18th. Finally, Morgan Stanley lowered Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $56.00 to $11.00 in a research note on Monday, January 27th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Stock Up 4.5 %

Shares of NASDAQ NTLA opened at $10.35 on Monday. The business has a fifty day simple moving average of $10.61 and a two-hundred day simple moving average of $15.07. The firm has a market cap of $1.07 billion, a PE ratio of -1.90 and a beta of 1.97. Intellia Therapeutics, Inc. has a twelve month low of $8.30 and a twelve month high of $32.00.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.